Published in Proc Natl Acad Sci U S A on January 20, 1998
Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis (SLAM-2) | NCT02737202
VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol (2003) 12.96
Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J (2001) 3.88
Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci U S A (1998) 3.72
Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J Exp Med (2002) 3.16
VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol (1999) 3.09
Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J (2001) 3.00
Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am J Pathol (2001) 2.89
Molecular characterization of lymphatic endothelial cells. Proc Natl Acad Sci U S A (2002) 2.68
Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci U S A (1998) 2.32
Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea. Proc Natl Acad Sci U S A (2002) 2.30
Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res (2000) 2.13
Dose-dependent response of FGF-2 for lymphangiogenesis. Proc Natl Acad Sci U S A (2004) 1.98
Vascular endothelial growth factors and vascular permeability. Cardiovasc Res (2010) 1.89
Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis. Br J Cancer (1999) 1.87
Current views on the function of the lymphatic vasculature in health and disease. Genes Dev (2010) 1.84
Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc Natl Acad Sci U S A (2004) 1.82
Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer (2009) 1.78
The lymphatic system in health and disease. Lymphat Res Biol (2008) 1.78
Expression of vascular endothelial growth factor D is associated with hypoxia inducible factor (HIF-1alpha) and the HIF-1alpha target gene DEC1, but not lymph node metastasis in primary human breast carcinomas. J Clin Pathol (2004) 1.72
The lymphangiogenic vascular endothelial growth factors VEGF-C and -D are ligands for the integrin alpha9beta1. J Biol Chem (2004) 1.69
Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors. Am J Pathol (1998) 1.66
Comparative analysis of paracrine factor expression in human adult mesenchymal stem cells derived from bone marrow, adipose, and dermal tissue. Stem Cells Dev (2012) 1.61
Doxycycline reduces plasma VEGF-C/sVEGFR-3 and improves pathology in lymphatic filariasis. PLoS Pathog (2006) 1.57
First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours. Br J Cancer (2006) 1.53
Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer. PLoS One (2009) 1.53
Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases. Chest (2010) 1.52
Vascular endothelial growth factor (VEGF)-like protein from orf virus NZ2 binds to VEGFR2 and neuropilin-1. Proc Natl Acad Sci U S A (1999) 1.51
Angiogenesis in cancer. Vasc Health Risk Manag (2006) 1.49
c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro. Proc Natl Acad Sci U S A (1999) 1.49
Lymphangiogenesis and lymphatic metastasis in breast cancer. Pathophysiology (2009) 1.48
Deletion of vascular endothelial growth factor C (VEGF-C) and VEGF-D is not equivalent to VEGF receptor 3 deletion in mouse embryos. Mol Cell Biol (2008) 1.47
Vascular endothelial growth factor D is dispensable for development of the lymphatic system. Mol Cell Biol (2005) 1.47
Lymphangiogenesis and cancer metastasis. J Cell Mol Med (2009) 1.47
Enhanced Mitogenic Activity of Recombinant Human Vascular Endothelial Growth Factor VEGF121 Expressed in E. coli Origami B (DE3) with Molecular Chaperones. PLoS One (2016) 1.38
VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression. Neoplasia (2001) 1.37
Characterization of lymphangiogenesis in a model of adult skin regeneration. Am J Physiol Heart Circ Physiol (2006) 1.35
Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D. J Exp Med (2003) 1.35
Generation and characterization of telomerase-transfected human lymphatic endothelial cells with an extended life span. Am J Pathol (2004) 1.35
Vascular endothelial growth factor receptor-2 in breast cancer. Biochim Biophys Acta (2010) 1.32
Lymphatic endothelium: morphological, molecular and functional properties. J Cell Biol (2003) 1.31
Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer. Am J Pathol (2006) 1.30
Targeting lymphangiogenesis to prevent tumour metastasis. Br J Cancer (2006) 1.30
Lymphangiogenic gene therapy with minimal blood vascular side effects. J Exp Med (2002) 1.29
Novel expression of vascular endothelial growth factor receptor (VEGFR)-3 and VEGF-C on corneal dendritic cells. Am J Pathol (2003) 1.28
Lack of lymphangiogenesis during breast carcinogenesis. J Clin Pathol (2004) 1.25
Targeting non-malignant disorders with tyrosine kinase inhibitors. Nat Rev Drug Discov (2010) 1.24
From germline towards somatic mutations in the pathophysiology of vascular anomalies. Hum Mol Genet (2009) 1.23
Lymphatics at the crossroads of angiogenesis and lymphangiogenesis. J Anat (2004) 1.22
Vegfc is required for vascular development and endoderm morphogenesis in zebrafish. EMBO Rep (2004) 1.21
Role of shear-stress-induced VEGF expression in endothelial cell survival. J Cell Sci (2012) 1.21
Filariasis and lymphoedema. Parasite Immunol (2009) 1.20
Blockade of VEGFR3-signalling specifically inhibits lymphangiogenesis in inflammatory corneal neovascularisation. Graefes Arch Clin Exp Ophthalmol (2007) 1.20
Immunopathogenesis of lymphatic filarial disease. Semin Immunopathol (2012) 1.19
Glomeruloid microvascular proliferation orchestrated by VPF/VEGF: a new world of angiogenesis research. Am J Pathol (2001) 1.19
Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma. Br J Cancer (2003) 1.18
Lymphatic vessels as targets of tumor therapy? J Exp Med (2001) 1.17
Distinct roles of vascular endothelial growth factor-D in lymphangiogenesis and metastasis. Am J Pathol (2007) 1.16
The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer. Br J Cancer (2001) 1.16
Lymphangiogenesis and cancer. Genes Cancer (2011) 1.16
Vascular endothelial growth factor in heart failure. Nat Rev Cardiol (2013) 1.16
Quantification and cell-to-cell variation of vascular endothelial growth factor receptors. Exp Cell Res (2010) 1.14
Role of VEGF-C and VEGF-D in lymphangiogenesis in gastric cancer. Int J Clin Oncol (2005) 1.11
Blood vessel endothelial VEGFR-2 delays lymphangiogenesis: an endogenous trapping mechanism links lymph- and angiogenesis. Blood (2010) 1.09
Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin). Ocul Surf (2012) 1.08
Developmental and pathological lymphangiogenesis: from models to human disease. Histochem Cell Biol (2008) 1.07
Macrophage-mediated lymphangiogenesis: the emerging role of macrophages as lymphatic endothelial progenitors. Cancers (Basel) (2012) 1.06
The role of growth factors and cytokines during implantation: endocrine and paracrine interactions. Semin Reprod Med (2009) 1.03
Lymphatic and angiogenic candidate genes predict the development of secondary lymphedema following breast cancer surgery. PLoS One (2013) 1.02
Hypoxia increases breast cancer cell-induced lymphatic endothelial cell migration. Neoplasia (2008) 1.00
Vascular endothelial growth factor A (VEGF-A) is involved in guidance of VEGF receptor-positive cells to the anterior portion of early embryos. Mol Cell Biol (2005) 1.00
Vascular endothelial growth factors C and D and lymphangiogenesis in gastrointestinal tract malignancy. Br J Cancer (2003) 1.00
Neuroblastoma progression correlates with downregulation of the lymphangiogenesis inhibitor sVEGFR-2. Clin Cancer Res (2010) 0.99
VEGF-D expression correlates with colorectal cancer aggressiveness and is downregulated by cetuximab. World J Gastroenterol (2008) 0.98
Tumor lymphangiogenesis as a potential therapeutic target. J Oncol (2012) 0.97
Human herpesvirus-8-transformed endothelial cells have functionally activated vascular endothelial growth factor/vascular endothelial growth factor receptor. Am J Pathol (2002) 0.97
Breakpoint analysis of Turner patients with partial Xp deletions: implications for the lymphoedema gene location. J Med Genet (2001) 0.97
Identification of genes differentially expressed in myogenin knock-down bovine muscle satellite cells during differentiation through RNA sequencing analysis. PLoS One (2014) 0.96
Vascular endothelial growth factor family members are differentially regulated by c-erbB signaling in head and neck squamous carcinoma cells. Clin Exp Metastasis (2000) 0.95
New model of macrophage acquisition of the lymphatic endothelial phenotype. PLoS One (2012) 0.95
Lymphangiogenesis is required for pancreatic islet inflammation and diabetes. PLoS One (2011) 0.95
Radiogenic lymphangiogenesis in the skin. Am J Pathol (2007) 0.95
The effect of vascular endothelial growth factor in the progression of bladder cancer and diabetic retinopathy. Int J Clin Exp Med (2013) 0.94
Differential gene expression of primary cultured lymphatic and blood vascular endothelial cells. Neoplasia (2007) 0.94
Small peptides derived from somatotropin domain-containing proteins inhibit blood and lymphatic endothelial cell proliferation, migration, adhesion and tube formation. Int J Biochem Cell Biol (2011) 0.94
CRSBP-1/LYVE-l-null mice exhibit identifiable morphological and functional alterations of lymphatic capillary vessels. FEBS Lett (2006) 0.94
Functional analyses of the bone marrow kinase in the X chromosome in vascular endothelial growth factor-induced lymphangiogenesis. Arterioscler Thromb Vasc Biol (2010) 0.94
The connection between lymphangiogenic signalling and prostaglandin biology: a missing link in the metastatic pathway. Oncotarget (2012) 0.94
Lymphatic development. Birth Defects Res C Embryo Today (2009) 0.93
What is the role of vascular endothelial growth factor-related molecules in tumor angiogenesis? Am J Pathol (1998) 0.93
Emerging Role of Sphingosine-1-phosphate in Inflammation, Cancer, and Lymphangiogenesis. Biomolecules (2013) 0.93
Expression of lymphangiogenic factors and evidence of intratumoral lymphangiogenesis in pancreatic endocrine tumors. Am J Pathol (2004) 0.92
Prognostic significance of vascular endothelial growth factor D in gastric carcinoma. World J Surg (2005) 0.92
Macrophages regulate corpus luteum development during embryo implantation in mice. J Clin Invest (2013) 0.92
Potential therapeutic strategies for lymphatic metastasis. Microvasc Res (2007) 0.92
Lymphatic vessel density and prognosis in cutaneous melanoma. Br J Cancer (2004) 0.92
Localisation of lymphatic vessels and vascular endothelial growth factors-C and -D in human and mouse skeletal muscle with immunohistochemistry. Histochem Cell Biol (2006) 0.92
The VEGF signaling pathway in cancer: the road ahead. Chin J Cancer (2013) 0.91
Lymphatic vessel density and function in experimental bladder cancer. BMC Cancer (2007) 0.91
A new method for predicting signal sequence cleavage sites. Nucleic Acids Res (1986) 37.19
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature (1996) 18.47
Mechanisms of angiogenesis. Nature (1997) 18.04
Rapid and sensitive sequence comparison with FASTP and FASTA. Methods Enzymol (1990) 17.64
Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature (1996) 16.92
Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (1983) 15.43
The I.M.A.G.E. Consortium: an integrated molecular analysis of genomes and their expression. Genomics (1996) 11.71
Angiogenesis. J Biol Chem (1992) 11.29
Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system. Proc Natl Acad Sci U S A (1987) 10.38
High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell (1993) 7.14
Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A (1995) 7.11
Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science (1997) 6.37
Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem (1994) 6.18
A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J (1996) 5.33
Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development (1992) 4.69
Expression cloning of the murine erythropoietin receptor. Cell (1989) 4.59
Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem (1994) 4.41
Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J (1997) 4.07
Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci U S A (1991) 3.95
Molecular cloning of cDNA for murine interleukin-3. Nature (1984) 3.50
Tie-1 and tie-2 define another class of putative receptor tyrosine kinase genes expressed in early embryonic vascular system. Proc Natl Acad Sci U S A (1993) 3.37
VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development (1996) 2.82
Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. Proc Natl Acad Sci U S A (1996) 2.77
A structural superfamily of growth factors containing a cystine knot motif. Cell (1993) 2.71
Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci U S A (1996) 2.71
Differentiation of endothelium. FASEB J (1995) 2.67
c-fos is required for malignant progression of skin tumors. Cell (1995) 2.39
Vascular endothelial growth factor, a potent and selective angiogenic agent. J Biol Chem (1996) 2.17
Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14. Oncogene (1993) 1.83
Purification and characterization of a naturally occurring vascular endothelial growth factor.placenta growth factor heterodimer. J Biol Chem (1995) 1.68
Two human FLT4 receptor tyrosine kinase isoforms with distinct carboxy terminal tails are produced by alternative processing of primary transcripts. Oncogene (1993) 1.61
AIDS-associated Kaposi's sarcoma cells in culture express vascular endothelial growth factor. Biochem Biophys Res Commun (1992) 1.60
Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family. Proc Natl Acad Sci U S A (1996) 1.44
PDGF-AA and PDGF-BB biosynthesis: proprotein processing in the Golgi complex and lysosomal degradation of PDGF-BB retained intracellularly. J Cell Biol (1992) 1.09
Fos and bone cell development: lessons from a nuclear oncogene. Trends Genet (1995) 0.98
Balbiani ring 3 in Chironomus tentans encodes a 185-kDa secretory protein which is synthesized throughout the fourth larval instar. Gene (1990) 0.95
Hybrid tyrosine kinase/cytokine receptors transmit mitogenic signals in response to ligand. J Biol Chem (1994) 0.85
Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature (1983) 8.18
Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med (2001) 7.78
Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A (1995) 7.11
Homogeneously staining chromosomal regions contain amplified copies of an abundantly expressed cellular oncogene (c-myc) in malignant neuroendocrine cells from a human colon carcinoma. Proc Natl Acad Sci U S A (1983) 7.01
Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science (1997) 6.37
A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J (1996) 5.33
Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science (1998) 5.07
Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol (1999) 5.02
Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J (2001) 4.70
Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci U S A (1999) 4.52
Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med (2001) 4.50
ICAM-1 (CD54): a counter-receptor for Mac-1 (CD11b/CD18). J Cell Biol (1990) 4.39
Clinical applications of angiogenic growth factors and their inhibitors. Nat Med (1999) 4.26
Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. Science (1994) 4.24
Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J (1997) 4.07
Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J (2001) 3.88
Identification of nuclear proteins encoded by viral and cellular myc oncogenes. Nature (1984) 3.86
PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor. Nat Cell Biol (2000) 3.81
Polypeptide signalling to the nucleus through tyrosine phosphorylation of Jak and Stat proteins. Nature (1993) 3.73
Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci U S A (1998) 3.72
Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat Genet (2000) 3.66
A cellular oncogene (c-Ki-ras) is amplified, overexpressed, and located within karyotypic abnormalities in mouse adrenocortical tumour cells. Nature (1983) 3.56
Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res (2001) 3.38
FGFR-4, a novel acidic fibroblast growth factor receptor with a distinct expression pattern. EMBO J (1991) 3.19
Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Cell (1995) 3.17
The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. EMBO J (1995) 3.16
VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol (1999) 3.09
Characterization of ICAM-2 and evidence for a third counter-receptor for LFA-1. J Exp Med (1991) 3.08
Endothelial receptor tyrosine kinases involved in angiogenesis. J Cell Biol (1995) 3.06
Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J (2001) 3.00
Vascular abnormalities and deregulation of VEGF in Lkb1-deficient mice. Science (2001) 2.99
Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am J Pathol (2001) 2.89
A model for gene therapy of human hereditary lymphedema. Proc Natl Acad Sci U S A (2001) 2.88
Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem (1994) 2.87
Vascularization of the mouse embryo: a study of flk-1, tek, tie, and vascular endothelial growth factor expression during development. Dev Dyn (1995) 2.83
VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development (1996) 2.82
Induction of a basement membrane glycoprotein in embryonic kidney: possible role of laminin in morphogenesis. Proc Natl Acad Sci U S A (1980) 2.74
Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci U S A (1996) 2.71
PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor. Nat Cell Biol (2001) 2.70
Repression of cyclin D1: a novel function of MYC. Mol Cell Biol (1994) 2.67
Nucleotide sequence to the v-myc oncogene of avian retrovirus MC29. Proc Natl Acad Sci U S A (1983) 2.66
Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res (2000) 2.64
Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res (2000) 2.63
Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. Cancer Res (1998) 2.60
Oncogene amplification in tumor cells. Adv Cancer Res (1986) 2.44
Fibronectin is produced by human macrophages. J Exp Med (1980) 2.44
VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. Dev Biol (1997) 2.43
A novel endothelial cell surface receptor tyrosine kinase with extracellular epidermal growth factor homology domains. Mol Cell Biol (1992) 2.34
Regulation of adhesion of ICAM-1 by the cytoplasmic domain of LFA-1 integrin beta subunit. Science (1991) 2.34
Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci U S A (1998) 2.32
Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C. J Biol Chem (1998) 2.28
VEGFs, receptors and angiogenesis. Semin Cancer Biol (1999) 2.25
Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. Am J Pathol (2000) 2.24
Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci U S A (2001) 2.19
Isolation of the pericellular matrix of human fibroblast cultures. J Cell Biol (1979) 2.19
Two forms of the basic fibroblast growth factor receptor-like mRNA are expressed in the developing mouse brain. Proc Natl Acad Sci U S A (1990) 2.17
The human p50csk tyrosine kinase phosphorylates p56lck at Tyr-505 and down regulates its catalytic activity. EMBO J (1992) 2.16
Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes (1999) 2.16
Structure and sequence of the promoter area and of a 5' upstream demethylation site of the estrogen-regulated chicken vitellogenin ii gene. J Biol Chem (1983) 2.11
VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues. FASEB J (2000) 2.06
Tie receptors: new modulators of angiogenic and lymphangiogenic responses. Nat Rev Mol Cell Biol (2001) 2.05
FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines. Cancer Res (1992) 1.99
A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities. J Biol Chem (1998) 1.98
Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors. Cancer (1999) 1.97
Identification and cloning of a protein kinase-encoding mouse gene, Plk, related to the polo gene of Drosophila. Proc Natl Acad Sci U S A (1993) 1.96
Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2. Cardiovasc Res (2001) 1.95
A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J (1996) 1.95
Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers. J Biol Chem (1999) 1.94
Biosynthesis of two subunits of type IV procollagen and of other basement membrane proteins by a human tumor cell line. Eur J Biochem (1980) 1.90
Determining the cause of death in randomized screening trial(s) for prostate cancer. BJU Int (2003) 1.90
JAK2, a third member of the JAK family of protein tyrosine kinases. Oncogene (1992) 1.88
Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis. Br J Cancer (1999) 1.87
Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase. Am J Hum Genet (2000) 1.86
Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia. Oncogene (1997) 1.85
Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14. Oncogene (1993) 1.83
Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thromb Haemost (1998) 1.80
Structure, expression and receptor-binding properties of novel vascular endothelial growth factors. Curr Top Microbiol Immunol (1999) 1.79
Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis. Blood (2000) 1.76
Signalling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors. Oncogene (1994) 1.73
Adenoviral expression of vascular endothelial growth factor-C induces lymphangiogenesis in the skin. Circ Res (2001) 1.71
Kinase-negative mutants of JAK1 can sustain interferon-gamma-inducible gene expression but not an antiviral state. EMBO J (1996) 1.71
Enhanced jun gene expression is an early genomic response to transforming growth factor beta stimulation. Mol Cell Biol (1989) 1.70
Alternative forms of Max as enhancers or suppressors of Myc-ras cotransformation. Science (1992) 1.70
Mutagenesis and selection of PDZ domains that bind new protein targets. Nat Biotechnol (1999) 1.69
Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors. Am J Pathol (1998) 1.66
Ryk-deficient mice exhibit craniofacial defects associated with perturbed Eph receptor crosstalk. Nat Genet (2000) 1.66